The Quantellect read.As of Nov 19, 2026, 13 active firms cover Denali Therapeutics Inc: 12 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $23.00 to $42.00, a moderate spread. The average target of $35.25 sits 91% above the current $18.41. The rating mix has stayed broadly stable, with Buy-side ratings easing from 13 to 12 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.64 next quarter toward $-2.26 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS13 active firms
Buy
Strong Buy00%
Buy1292%
Neutral18%
Sell00%
Strong Sell00%
Based on 13 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$35.25
+91.5% upside
Average target across 12 active firms as of Nov 19, 2026 vs $18.41 current
Highest Target$42.00
Average Target$35.25
Lowest Target$23.00
Detailed analyst forecasts for DNLI
Showing 1–13 of 13 named analysts shown · 13 active firms in the rating projection
As of Nov 19, 2026, 12 of 13 active firms rate DNLI a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
DNLI EPS & revenue forecast
EPS · NEXT QUARTER
$-0.64
Range $-0.69 – $-0.58 · 3 analysts · -7% YoY
Next period, 3 analysts expect Denali Therapeutics Inc to earn $-0.64 a share (range $-0.69 – $-0.58), versus $-0.69 a year earlier. Full-year consensus is $-2.00, growing to $-2.26 the year after.
REVENUE · NEXT QUARTER
$39.7M
Range $31.7M – $51.3M · 3 analysts
Revenue is expected to reach $39.7M (range $31.7M – $51.3M). Full-year consensus is $53.9M, rising to $164.3M next year.
Top analysts covering Denali Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DNLI.
#1
Mayank Mamtani
B. Riley Securities · Rank #36
Buy
$35.00+90.1% to target
Overall win rate
49%
+ Follow
#2
Laura Chico
Wedbush · Rank #55
Buy
$26.00+41.2% to target
Overall win rate
46%
+ Follow
#3
Joel Beatty
Baird · Rank #71
Buy
$34.00+84.7% to target
Overall win rate
50%
+ Follow
#4
Andrew Fein
HC Wainwright & Co. · Rank #73
Buy
$42.00+128.1% to target
Overall win rate
45%
+ Follow
#5
Jessica Fye
JP Morgan · Rank #100
Buy
$29.00+57.5% to target
Overall win rate
54%
+ Follow
DNLI stock forecast FAQ
What is DNLI's average 12-month price target?+
The 12 active firms with a live target average $35.25 for Denali Therapeutics Inc over the next 12 months, ranging from a $42.00 high to a $23.00 low, as of Nov 19, 2026.
Is DNLI stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 13 active firms as of Nov 19, 2026, 12 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for DNLI?+
The Street-high target is $42.00 (HC Wainwright & Co.), and the Street-low is $23.00 (Wedbush). The average of all 12 active-firm targets is $35.25.
How many active Wall Street firms cover DNLI?+
13 active firms have a recognized rating on Denali Therapeutics Inc as of Nov 19, 2026, and 12 active firms carry a live 12-month price target.
Who is the most accurate analyst covering DNLI?+
Among analysts who currently cover DNLI, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #36). Their current call is Buy with a $35.00 target.
What is Denali Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.64 per share (range $-0.69 – $-0.58) across 3 analysts. Full-year EPS is projected at $-2.00, rising to $-2.26 the following year.
How much revenue is Denali Therapeutics Inc expected to report next quarter?+
Consensus revenue is $39.7M (range $31.7M – $51.3M). Full-year revenue is projected at $53.9M, growing to $164.3M next year.
Have analysts been upgrading or downgrading DNLI lately?+
As of Nov 19, 2026, 12 of 13 active firms rate DNLI a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DNLI calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.